Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 91.39% is in line with its 5-year average of 94.37%, around the middle of its 5-year range (85.49%–99.51%).
0.99% below its 12-month average of 92.31%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 89.17%.
GROSS MARGIN
91.39%
GROSS MARGIN AVG TTM
92.31%
GROSS MARGIN AVG 3Y
91.93%
GROSS MARGIN AVG 5Y
94.37%
GROSS MARGIN AVG 10Y
95.97%
GROSS MARGIN AVG 15Y
62.95%
GROSS MARGIN AVG 20Y
60.74%
CURRENT VS TTM AVG
-0.99%
CURRENT VS 3Y AVG
-0.59%
CURRENT VS 5Y AVG
-3.16%
CURRENT VS 10Y AVG
-4.77%
CURRENT VS 15Y AVG
+45.19%
CURRENT VS 20Y AVG
+50.46%
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+120.86%
vs the sector median at left
Rigel Pharmaceuticals, Inc.
Market Cap
$853.13M
Gross Margin
91.39%
TTM Avg
92.31%
3Y Avg
91.93%
5Y Avg
94.37%
Market Cap
$852.35M
Gross Margin
35.27%
TTM Avg
46.37%
3Y Avg
58.90%
5Y Avg
58.90%
Market Cap
$857.16M
Gross Margin
44.60%
TTM Avg
46.45%
3Y Avg
50.53%
5Y Avg
59.76%
Market Cap
$838.62M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$838.16M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$870.81M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$833.81M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | $853.13M | 91.39% | 92.31% | 91.93% | 94.37% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | 35.27% | 46.37% | 58.90% | 58.90% |
| Alumis Inc. (ALMS)vs › | $855.38M | 88.23% | 42.73% | 21.36% | 21.36% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | 44.60% | 46.45% | 50.53% | 59.76% |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 79.53% | 79.30% | 80.66% | 83.15% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 35.97% | 27.94% | 30.11% | 34.47% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | 58.31% | 55.25% | 65.77% | 65.77% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | 100.00% | 100.00% | 100.00% | 100.00% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | 92.94% | 91.25% | 45.63% | 30.42% |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $828.48M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
91.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 89.17% |
| 2026-03-31 | 92.17% |
| 2025-12-31 | 91.47% |
| 2025-09-30 | 93.16% |
| 2025-06-30 | 95.57% |
| 2025-03-31 | 91.73% |
| 2024-12-31 | 89.95% |
| 2024-09-30 | 85.49% |
| 2024-06-30 | 92.38% |
| 2024-03-31 | 93.14% |
| 2023-12-31 | 89.41% |
| 2023-09-30 | 95.49% |
| 2023-06-30 | 96.00% |
| 2023-03-31 | 96.25% |
| 2022-12-31 | 99.33% |
| 2022-09-30 | 98.88% |
| 2022-06-30 | 96.53% |
| 2022-03-31 | 99.28% |
| 2021-12-31 | 97.61% |
| 2021-09-30 | 99.30% |
| 2021-06-30 | 99.51% |
| 2021-03-31 | 99.61% |
| 2020-12-31 | 98.26% |
| 2020-09-30 | 99.24% |
| 2020-06-30 | 98.26% |
| 2020-03-31 | 99.72% |
| 2019-12-31 | 98.84% |
| 2019-09-30 | 98.51% |
| 2019-06-30 | 97.01% |
| 2019-03-31 | 99.15% |
| 2018-12-31 | 99.50% |
| 2018-09-30 | 98.58% |
| 2018-06-30 | 98.32% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | -1100.89% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | -245.31% |
| 2016-12-31 | -287.80% |
| 2016-09-30 | -330.08% |
| 2016-06-30 | -103.26% |
| 2016-03-31 | -261.36% |
| 2015-12-31 | -94.01% |
| 2015-09-30 | -19.28% |
| 2015-06-30 | -190.49% |
| 2015-03-31 | -620.94% |
| 2014-12-31 | -77.13% |
| 2014-09-30 | 0.00% |
| 2014-06-30 | 0.00% |
| 2014-03-31 | 0.00% |
| 2013-12-31 | -213.84% |
| 2013-09-30 | 0.00% |
| 2013-06-30 | -1285.21% |
| 2013-03-31 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-09-30 | 0.00% |
| 2012-06-30 | 100.00% |
| 2012-03-31 | 100.00% |
| 2011-12-31 | 0.00% |
| 2011-09-30 | 100.00% |
| 2011-06-30 | 100.00% |
| 2011-03-31 | 0.00% |
| 2010-12-31 | 100.00% |
| 2010-09-30 | 100.00% |
| 2010-06-30 | 100.00% |
| 2010-03-31 | 100.00% |
| 2009-12-31 | 100.00% |
| 2009-09-30 | 0.00% |
| 2009-06-30 | 0.00% |
| 2009-03-31 | 0.00% |
| 2008-12-31 | 0.00% |
| 2008-09-30 | 0.00% |
| 2008-06-30 | 0.00% |
| 2008-03-31 | 0.00% |
| 2007-12-31 | 100.00% |
| 2007-09-30 | 0.00% |
| 2007-06-30 | 100.00% |
| 2007-03-31 | 100.00% |
| 2006-12-31 | 100.00% |
| 2006-09-30 | 100.00% |
| 2006-06-30 | 100.00% |
| 2006-03-31 | 100.00% |
| 2005-12-31 | 100.00% |
| 2005-09-30 | 100.00% |
| 2005-06-30 | 100.00% |
| 2005-03-31 | 100.00% |
| 2004-12-31 | 100.00% |
| 2004-09-30 | 100.00% |
| 2004-06-30 | 100.00% |
| 2004-03-31 | 100.00% |
| 2003-12-31 | 100.00% |
| 2003-09-30 | 100.00% |
| 2003-06-30 | 100.00% |
| 2003-03-31 | 100.00% |
| 2002-12-31 | 100.00% |
| 2002-09-30 | 100.00% |
